{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T14:54:42Z","timestamp":1777560882131,"version":"3.51.4"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>An 81-year-old man prescribed isavuconazole for pulmonary fungal infection developed high serum transaminase levels and biopsy-confirmed hepatic necrosis associated with prolonged high serum isavuconazole levels. Genotyping revealed poor CYP3A5 activity\/normal CYP3A4 activity. Older age and slow isavuconazole elimination likely led to isavuconazole-associated hepatic toxicity. This case underscores the importance of isavuconazole therapeutic drug monitoring.<\/jats:p>","DOI":"10.1093\/ofid\/ofag090","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:49:22Z","timestamp":1772023762000},"source":"Crossref","is-referenced-by-count":2,"title":["Liver Necrosis in a Patient Receiving Isavuconazole: Making the Case for Therapeutic Drug Monitoring"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3175-0512","authenticated-orcid":false,"given":"Marisa H","family":"Miceli","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Michigan , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A","family":"Eschenauer","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, University of Michigan , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol A","family":"Kauffman","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Michigan , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"2026031116101653600_ofag090-B1","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole. a new broad-spectrum triazole antifungal agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026031116101653600_ofag090-B2","doi-asserted-by":"crossref","first-page":"e0017722","DOI":"10.1128\/aac.00177-22","article-title":"New perspectives on antimicrobial agents: isavuconazole","volume":"66","author":"Lewis","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031116101653600_ofag090-B3","doi-asserted-by":"crossref","first-page":"myae083","DOI":"10.1093\/mmy\/myae083","article-title":"A global perspective of the changing epidemiology of invasive fungal disease and real-world experience with the use of isavuconazole","volume":"62","author":"Thompson","year":"2024","journal-title":"Med Mycol"},{"key":"2026031116101653600_ofag090-B4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jac\/dky463","article-title":"Variability and exposure-response relationships of isavuconazole plasma concentrations in the phase 3 SECURE trial of patients with invasive mould diseases","volume":"74","author":"Kaindl","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026031116101653600_ofag090-B5","doi-asserted-by":"crossref","first-page":"e00585","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole concentration in real-world practice: consistency with results from clinical trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031116101653600_ofag090-B6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12281-022-00430-4","article-title":"Azole therapeutic drug monitoring and its use in the management of invasive fungal disease","volume":"16","author":"Ashok","year":"2022","journal-title":"Curr Fungal Infect Rep"},{"key":"2026031116101653600_ofag090-B7","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/phar.2850","article-title":"Utility of triazole antifungal therapeutic drug monitoring: insights from the Society of Infectious Diseases Pharmacists","volume":"43","author":"McCreary","year":"2023","journal-title":"Pharmacother"},{"key":"2026031116101653600_ofag090-B8","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2026031116101653600_ofag090-B9","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2026031116101653600_ofag090-B10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/mmy\/myz103","article-title":"Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system","volume":"58","author":"Schwartz","year":"2019","journal-title":"Med Mycol"},{"key":"2026031116101653600_ofag090-B11","doi-asserted-by":"crossref","first-page":"e01034","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031116101653600_ofag090-B12","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/myc.13469","article-title":"Isavuconazole therapeutic drug monitoring in critically ill ICU patients: a monocentric retrospective analysis","volume":"65","author":"Hohl","year":"2022","journal-title":"Mycoses"},{"key":"2026031116101653600_ofag090-B13","doi-asserted-by":"crossref","first-page":"e0057725","DOI":"10.1128\/aac.00577-25","article-title":"Low isavuconazole trough levels in critically ill patients with and without extracorporeal membrane oxygenation","volume":"69","author":"Erlebach","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031116101653600_ofag090-B14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/jof6020090","article-title":"Isavuconazole treatment in a mixed patient cohort with invasive fungal infections: outcome, tolerability, and clinical implications of isavuconazole plasma concentrations","volume":"6","author":"Zurl","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2026031116101653600_ofag090-B15","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Fufaro","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026031116101653600_ofag090-B16","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/jac\/dkaf128","article-title":"Isavuconazole therapeutic drug monitoring and association with adverse events","volume":"80","author":"Huang","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026031116101653600_ofag090-B17","doi-asserted-by":"crossref","first-page":"e01511","DOI":"10.1128\/AAC.01511-20","article-title":"Isavuconazole therapeutic drug monitoring during long-term treatment for chronic pulmonary aspergillosis","volume":"65","author":"Kosmidis","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031116101653600_ofag090-B18","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/INF.0000000000002418","article-title":"Isavuconazole-induced acute liver failure in a pediatric patient with invasive aspergillosis","volume":"38","author":"Brivio","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"2026031116101653600_ofag090-B19","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3390\/genes16091058","article-title":"The impact of genetic polymorphisms on the clinical efficacy of azole antifungals","volume":"16","author":"Singam","year":"2025","journal-title":"Genes (Basel)"},{"key":"2026031116101653600_ofag090-B20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cpdd.285","article-title":"Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol\/norethindrone in healthy adults","volume":"6","author":"Townsend","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2026031116101653600_ofag090-B21","doi-asserted-by":"crossref","first-page":"6730","DOI":"10.1038\/s41598-023-31788-1","article-title":"Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies","volume":"13","author":"Hamed","year":"2023","journal-title":"Sci Rep"},{"key":"2026031116101653600_ofag090-B22","doi-asserted-by":"crossref","first-page":"107070","DOI":"10.1016\/j.ijid.2024.107070","article-title":"Safety and effectiveness of isavuconazole in real-life non-neutropenic patients","volume":"144","author":"Monz\u00f3-Gallo","year":"2024","journal-title":"Int J Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag090\/67175297\/ofag090.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/3\/ofag090\/67175297\/ofag090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/3\/ofag090\/67175297\/ofag090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:10:24Z","timestamp":1773259824000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag090\/8502217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag090","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,28]]},"article-number":"ofag090"}}